Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | ATF4 | P18848 | 3/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 11/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4897732 | 0.95 | MEN1 (0.42) | ABCB11ATF4ADRB3ADRB2ADRB1 | |
| SCHEMBL4574895 | 0.95 | MEN1 (0.42) | ABCB11ATF4ADRB3ADRB2ADRB1 | |
| SCHEMBL4903835 | 0.93 | ABCB11 (0.39) | ABCB11ATF4ADRB3ADRB2ADRB1 | |
| SCHEMBL4892474 | 0.93 | ABCB11 (0.39) | ABCB11ATF4ADRB3ADRB2ADRB1 | |
| SCHEMBL4892652 | 0.93 | MEN1 (0.48) | ABCB11ATF4ADRB3ADRB2ADRB1 | |
| SCHEMBL4892699 | 0.93 | ADRB3 (0.43) | ABCB11ATF4ADRB3ADRB2ADRB1 | |
| SCHEMBL4923480 | 0.93 | MEN1 (0.48) | ABCB11ATF4ADRB3ADRB2ADRB1 | |
| SCHEMBL4897663 | 0.93 | ADRB3 (0.46) | ABCB11ATF4ADRB3ADRB2ADRB1 | |
| SCHEMBL4895738 | 0.93 | ADRB3 (0.43) | ABCB11ATF4ADRB3ADRB2ADRB1 | |
| SCHEMBL14046032 | 0.93 | ABCB11 (0.39) | ABCB11ATF4ADRB3ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255134-A1 | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase | ARTESIAN THERAPEUTICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255134-A1 | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase | ADRB3, PDE3A, ADRB1 | ABCB11 845/4885ATF4 1399/4885ADRB3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.